Table 4.
Baseline characteristics of participants with and without MALDI-TOF spectra
| Without (n = 230) | With (n = 329) | p value for difference* | |
|---|---|---|---|
| Males (%) | 74.3 (68.2;79.9) | 70.8 (65.6;75.7) | 0.358 |
| Age (years) | 50.5 (6.3) | 51.0 (6.1) | 0.420 |
| BMI (kg/m2) | 26.9 (4.6) | 26.4 (3.8) | 0.111 |
| Height (cm) | 173.6 (8.8) | 172.6 (9.2) | 0.268 |
| Diastolic blood pressure (mmHg) | 82.2 (9.8) | 80.7 (9.7) | 0.079 |
| Systolic blood pressure (mmHg) | 123.8 (13.7) | 121.7 (13.5) | 0.077 |
| Total cholesterol (mmol/l) | 6.7 (1.1) | 6.6 (1.2) | 0.437 |
| HDL cholesterol (mmol/l) | 1.4 (0.4) | 1.4 (0.4) | 0.745 |
| LDL cholesterol (mmol/l) | 4.5 (1.0) | 4.5 (1.1) | 0.820 |
| Triglycerides (mmol/l) | 1.8 (1.4) | 1.6 (1.0) | 0.008 |
| CRP (mg/l) | 0.9 (0.5;1.6) | 0.9 (0.5;2) | 0.400 |
| Smoking habits (%) | |||
| Never-smoker (%) | 54.8 (48.1;61.3) | 45.3 (39.8;50.8) | 0.027 |
| Ex-smoker (%) | 33.9 (27.8;40.4) | 34.0 (28.9;39.4) | 0.975 |
| Current smoker (%) | 6.1 (3.4;10.0) | 13.4 (9.9;17.5) | 0.004 |
| Fasting plasma glucose (mmol/l) | 5.2 (0.5) | 5.2 (0.5) | 0.991 |
| 2-h plasma glucose (mmol/l) | 5.8 (1.7) | 5.4 (1.6) | 0.020 |
| Anti-hypertensive treatment (%) | 7.4 (4.4;11.6) | 8.5 (5.7;12.1) | 0.631 |
| Lipid-lowering treatment (%) | 0.0 (0.0;1.6) | 0.9 (0.2;2.6) | 0.074 |
Data are means (SD), medians (interquartile range) or proportions (95% CI).
*
After controlling for multiple testing, there were no significant differences in characteristics between the two groups